Rucaparib is a potent (Ki<5 nM) PARP1 inhibitor. Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2. Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines. Synergizes with other anticancer agents such as topotecan,...
Know who made it. See the evidence. Buy through one marketplace.
Rucaparib is a potent (Ki<5 nM) PARP1 inhibitor. Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2. Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines. Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel and temozolamide. Ameliorates the cardiotoxicity of doxorubicin. Recently approved for human use by the FDA
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
PARP1 identifies poly(ADP-ribose) polymerase 1 in Homo sapiens (Human). This target record connects NCBI Gene 142, UniProtKB P09874 and related ABMIUM catalogue products.
